EP0885015A2 - Cytokines modifiees pour usage therapeutique - Google Patents

Cytokines modifiees pour usage therapeutique

Info

Publication number
EP0885015A2
EP0885015A2 EP97903285A EP97903285A EP0885015A2 EP 0885015 A2 EP0885015 A2 EP 0885015A2 EP 97903285 A EP97903285 A EP 97903285A EP 97903285 A EP97903285 A EP 97903285A EP 0885015 A2 EP0885015 A2 EP 0885015A2
Authority
EP
European Patent Office
Prior art keywords
ligand
tnf
tumoral
biotinylated
biotin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97903285A
Other languages
German (de)
English (en)
Inventor
Angelo Corti
Antonio Siccardi
Paolo Dellabona
Giulia Casorati
Micaela Pelagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondazione Centro San Raffaele del Monte Tabor
Original Assignee
Fondazione Centro San Raffaele del Monte Tabor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Centro San Raffaele del Monte Tabor filed Critical Fondazione Centro San Raffaele del Monte Tabor
Publication of EP0885015A2 publication Critical patent/EP0885015A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention refers to modified cytokines for therapeutic use.
  • the immune system produces cytokines and other humoural factors in response to different inflammatory stimuli, to traumas, to viral and bacteriological infections or to signals of cell degeneration, such as cancer.
  • terms like “lymphokine”, “monokines” and “cytokines” have been initially coined in order to distinguish products deriving from lymphocytes, monocytes and non-ly phoid cells, afterwards a sort of overlapping between these categories came out.
  • the term “cytokines” is in current used as a synonymous of "lymphokines” and “monokines” and is hereinafter employed in this accepted meaning.
  • a list of most of the cytokines known in the art, as well as a list of their biological activities, is reported in Aggarwal B.B. and Pocsik E.
  • cytokines exert antitumoral, antiviral and antibacteric activity.
  • some cytokines have already been used therapeutically also in humans (De Vita et al., 1995, in Biologic Therapy of Cancer, Lippincott Company, Phyladelphia) .
  • IL-2 interleukine-2
  • IFN ⁇ interferon ⁇
  • IL-2 and IFN ⁇ have shown positive antitumoral activity in patients with different types of tumors, such as kidney metastatic carcinoma, hairy cell leukemia, Kaposi sarcoma, melanoma, multiple mieloma, etc.
  • cytokines like IFN ⁇ , the Tumor Necrosis Factor (TN ) ⁇ , TNF ⁇ , I -1, 4, 6, 12, 15 and the Colony Stimulating Factors (CFSs) have shown a certain antitumoral activity on some types of tumors and therefore are the object of further studies.
  • Other cytokines have been used in the therapy of infective diseases (Aggarwal B.B. e Pocsik E.).
  • cytokines In general, the therapeutic use of cytokines is strongly limited by their systemic toxicity. Since this represents a crucial problem for their use in humans in therapeutically active amounts, many attempts have been made to develop new cytokines derivatives and new therapeutic strategies aimed at reducing the toxic effects of this class of biological effectors maintaining their therapeutic efficacy.
  • Tumor Necrosis Factor ⁇ represents an emblematic case.
  • TNF is a cytokine, mainly secreted by macrophages, originally discovered for its capacity of inducing the hemorrhagic necrosis of some tumors (Carswell et al., 1975). Afterwards it has been demonstrated that TNF, besides exerting cytotoxic and cytostatic effects on different tumoral lines, can exert several other biological effects important for the regulation of the inflammatory and immune responses (Beutler and Cerami, 1989;Fier ⁇ , 1991). The idea is now confirmed that TNF can exert healthy or toxic effects for the organism by which is produced, as a function of its concentration, of its production site and of the time of persistence in the site of action. For example, the chronic exposition to low amounts of TNF can provoke cachexy while the acute hyper-production of TNF can cause serious vascular damages, shock and even death (Beutler and Cerami,
  • TNF TNF-tumoral activity exerted in vivo by TNF mostly depends on its capacity of inducing damages to the tumor vascular system through direct effects on the endotheliu and, in addition, through the activation of the inflammatory and immune responses (Sidhu and Bollon, 1993). On the contrary, less importance has been given to TNF-tumoral cells' direct cytotoxicity.
  • TNF-based strategies are now under evaluation, aimed at increasing therapeutic efficacy of TNF through an increase in the highest-tolerated amount and a reduction in the systemic toxic effects, obviously without jeopardize the antitumoral activity. It has been estimated that a reduction of about one order of magnitude of the amount necessary for exerting an antitumoral effect could result well tolerated.
  • EP 251 494 describes a system for administering a diagnostic or therapeutic agent, which comprises: an antibody conjugated with avidin or streptavidin, an agent capable of complexing the conjugated antibody and a compound consisting of the diagnostic or therapeutic agent conjugated with biotin, which are administered sequentially and adequately delayed, so as to allow the localization of the therapeutic or diagnostic agent through the biotin- streptavidin interaction on the target cell recognized by the antibody.
  • the described therapeutic or diagnostic agents comprise metallic chelates, in particular chelates of radionuclide ⁇ and low molecular weight antitumoral agents such as cis-platinum, doxorubicin, etc.
  • metallic chelates in particular chelates of radionuclide ⁇ and low molecular weight antitumoral agents such as cis-platinum, doxorubicin, etc.
  • the system is not suitable for compounds with molecular weights over 50,000 Daltons (preferably not over 10,000 daltons), and necessarily cannot be applied to cytokines, such as TNF (51,000).
  • EP 496 074 describes a method which provides the sequential administration of a biotinylated antibody, avidin or streptavidin and a biotinylated diagnostic or therapeutic agent. Also in this case, even though cytotoxic agents like ricin (a protein whose cytotoxic chain has a molecular weight of about 30,000 daltons) are mentioned, the application relative to radiolabelled compounds is mostly disclosed.
  • WO 95/15979 discloses a method for localizing highly toxic agents (I) on cellular targets, based on the administration of a first conjugate (Cl) comprising the specific target molecule conjugated with a ligand
  • a second conjugate (C2) consisting of the toxic agent (I) bound to an anti-ligand (AL) or to the ligand (L).
  • cytokines are cited among the toxic agents (I), including TNF, as well as the avidm/biotin system for L/AL, it can be deduced that when cytokines are used, the administration of the ligand (L) or (AL) is highly preferred for dissociating the cytokine thus allowing the "free" cytokme to exert the biological effects. This is likely due to the fact that the bound cytokine cannot react with its own receptors and exert efficaciously the desired biological effects.
  • L or AL The necessary amount of L or AL is expected to be relatively high in order to compete for the binding on the cell surface, with possible consequent problems of toxicity.
  • WO 95/15979 reports no specific experimental data which support the use of cytokines in the claimed method, but only generical citations that are not sufficient to provide the reproducible and practical teaching necessary for applying the method for localization to this class of substances that moreover do not act through a simple cytotoxic mechanism, but also through complex pro-inflammatory, lmmunostiulating, procoagulant and necrotizmg mechanisms by which such substances can exert antitumoral effects without exerting direct cytotoxic effects, as on the contrary it is required by using the agents of the above-mentioned applications EP-251 494 and EP-496 074.
  • cytokines can be localized efficaciously in a biological active form only by means of a system in which the interaction between the conjugated cytokine and the target specific-conjugated component is not direct, as is the case of conjugation of a ligand/antiligand couple, but is rather mediated by a third component which can bind as a bridge between the target specific- component and the cytokine.
  • the cytokine can also operate in a bound state and the administration of a member of the ligand/anti-ligand couple is not necessary in order to turn the cytokine in an active form.
  • compositions in the form of combined preparations for sequential therapeutic use comprising: a) an anti-pathologic target compound conjugated to a ligand of an at least ternary ligand/anti- ligand/ligand system; b) an anti-ligand complementary to the ligand of compound a); c) a cytokine conjugated to a ligand complementary to the anti-ligand b), with the proviso that the interaction ligand/anti-ligand/ligand is characterized by an affinity at least one order of magnitude higher than the affinity between the cytokine and its natural receptors.
  • Examples of compounds that can be conjugated to compound a) and to the cytokine, according to the invention, comprise haptens such as biotin and digoxigenin, while examples of "anti-ligand” compounds comprise anti-haptens antibodies (for example, anti- biotin antibodies and anti-digoxigenin antibodies) or, when biotin is used as a ligand, avidin and its analogues (e.g. streptavidin, neutravidin) .
  • haptens such as biotin and digoxigenin
  • anti-ligand comprise anti-haptens antibodies (for example, anti- biotin antibodies and anti-digoxigenin antibodies) or, when biotin is used as a ligand, avidin and its analogues (e.g. streptavidin, neutravidin) .
  • both compound a) and the cytokine are conjugated to biotin, while avidin (or the analogue compound) is used as an anti-ligand.
  • biotin or the analogue compound
  • avidin or the analogue compound
  • the anti-pathological target-compounds a) preferably are whole or fragmentary antibodies or monoclonal antibodies. Said antibodies have already been described and used widely, expecially in the case of antibodies directed against tumoral antigens.
  • LPS LPS or derivatives thereof
  • cytokines can sometimes exert additive or synergic effects
  • the strategy upon which the present invention is based can be performed in order to obtain synergic local effects and less effects at systemic level.
  • the biologic therapy of cancer and the effects of the combination of different cytokines' are widely documented and well summarized by De Vita et al. 1995 (Biologic Therapy of Cancer, Lippincott Company, Phyladelphia) .
  • TNF TNF is particularly preferred.
  • the mutual interactions of the conjugates or their interactions with the artificial receptor will be characterized by affinity constants at least one order of magnitude higher than the affinity constants of the cytokines' membrane receptors and by kinetic dissociation constants at least one order of magnitude lower than that of interaction of cytokine with its natural receptors.
  • the anti-target compound or conjugated antibody can be locally administered or alternatively can be injected into the bloodstream, and can be reacted jji vivo with the antigens or with the recognized cellular structures till the exceeding circulating compound or antibody is removed from the body, while a significant fraction remains bound to the pathological target.
  • the anti-ligand b) can be administered, followed by the conjugated cytokine in such a concentration that a bond with the antibody or anti-target compound can be formed thus allowing the mound or the increased persistence of the cytokines in the target cells.
  • bio-TNF biotinylated antibody specific for a tumoral antigen, neutravidin, and biotin-TNF
  • bio-TNF biotin-TNF
  • the affinity between bio-TNF and the artificial receptor (avidin) equal to 10 ⁇ 15 M
  • the affinity between bio-TNF and its natural receptors (TNF-R1 and TNF-R2) equal to 10 ⁇ 9 - 10 ⁇ 10 M
  • a biotinylated monoclonal antibody specific for a tumoral antigen is brought into contact with the tumor through its intra- or para-lesional, intra-cavity (e.g. bladder, peritoneal cavity), intra-artery (liver, central nervous system) administrations or at the systemic level, local or regional vascular perfusions (e.g. in the limb perfusional liquid, liver, breast), followed by analogue sequential administration of neutravidin or streptavidin and TNF-biotin.
  • intra-cavity e.g. bladder, peritoneal cavity
  • intra-artery liver, central nervous system
  • local or regional vascular perfusions e.g. in the limb perfusional liquid, liver, breast
  • Incubation times of some hours are preferably inserted between each administration to allow the vascular system to eliminate the exceeding product thus obtaining a finer localization on the tumoral target.
  • TNF biotinylated at the amino terminal region (1-11 residues, VRSSSRTPSDK sequence) is preferred, so that the multivalent bond of TNF with its natural receptors is not hampered and its effects are not inactivated.
  • amino acids bearing groups which can be easily biotinylated through known techniques (lysine, cysteine, tyrosine, hystidine, etc. see Savage et al., Avidin-biotin chemistry: a handbook, Pierce Biotec Company), can be inserted in the same region through genetic engineering-techniques, or glycosylation signals, so that specific biotinylation of carbohydrate residues is obtained, for instance with biotin-hydrazide or derivatives thereof.
  • the biotinylation of TNF at the amino-terminal portion can be easily obtained as well by means of genetic engineering-techniques through the construction of conjugates of TNF and fragments of proteins directly biotinylated by the expression system.
  • An example of such proteins is represented by acetyl-CoA carboxyla ⁇ e from E. Coli, and by its C-terminal domain bearing the biotinylation site.
  • a biotinylation of the alpha-amino groups is preferred in order to keep the structure of biotin-TNF the closest to the structure of non-biotinylated TNF.
  • biotinylation can be done by using protocols for biotinylation based on the reaction of biotin-6-aminocaproyl-N- hydroxysuccinimide ester at a pH comprised between 5.5 and 7.5.
  • biotinylated TNF can be obtained such that the capability of interacting with avidin and with membrane receptors is maintained, by "mixing" the subunits from
  • TNF for example biotinylated according to one of the above-described methods, and from non-biotinylated TNF.
  • the mixing reaction is carried out incubating mixtures of biotinylated and non-biotinylated
  • TNF in a ratio of 1:3 for 24-72 hours, at 4'C.
  • Such forms of TNF conjugated at the N-terminal are new and represent a further aspect of the invention.
  • Kits containing suitable therapeutic materials can be prepared in order to make the commerce and the routinary use of the compositions of the invention easier.
  • a kit according to the present invention comprises: a vial containing 0.5 to 10 mg of biotinylated antibody; a vial containing 5 to 100 mg of avidin or streptavidin or neutravidin; - a vial containing 0.5 to 10 mg of biotinylated TNF
  • the method of the present invention offers some advantages compared to known methods, for example the advantages deriving from the direct conjugation of cytokines with antibodies:
  • TNF for which the amount of antibody is invariably variable
  • EXAMPLE 1 This example shows an application of the invention based on the system:
  • Pathological target A : B : C-cytokine
  • Pathological target murine lymphoma expressing the murine antigen Thy 1.1 (RMA cells genetically engineered in order to express the allele Thyl.1 (RMA Thy 1.1
  • A biotinylated anti-Thy 1.1 monoclonal, antibody (mAb bio-19E12).
  • C-cytokine biotin-TNF conjugate
  • ( : ) represents a non-covalent interaction, while (-) represents a covalent bond.
  • AH-BNHS biotin 6-aminocaproyl-N-hydroxysuccinimide ester
  • Colture medium sterile RPMI-1640 (Gibco 31870-025)
  • FCS Foetal Calf Serum
  • FCS Foetal Calf Serum
  • Example 1.1 Preparation of the biotinylated 19E12 mAb antibody (bio- 19E12) 1000 ⁇ l of a solution of the 19E12 mAb, 1 mg/ l in sodium bicarbonate pH 8.5, 34 ⁇ l of a sulfur-NHS-LC-Bio- tin solution, 1 mg/ml (molar ratio mAb/biotin: 1/24) were pipetted into an Eppendorf tube. The mixture was incubated at room temperature (23/24 ⁇ C) for 30 minutes. After incubation the mixture was dialyzed overnight against 2 litres of PBS at 4 ⁇ C and kept at +4'C.
  • bio-TNF cod.#C product is prepared according to example 1.1.1 except for the use of a conjugation buffer at pH 7.8.
  • Comparative solutions of bio-TNF are also prepared using different incu ⁇ bation buffers, various TNF/biotin molar ratios (see ta ⁇ ble 1).
  • Example 1.3 Determination of the biologic activity of biotinylated TNF on RMA Thy 1.1 C 1.2 cells.
  • the plate was incubated for 24 hours at 37°C, 5% C02. Furthermore, 10 ⁇ l of a thiazolyl blue solution (MTT), 5 mg/ml in PBS, were added to each well. After further 4 hour incubation at 37 * C, 5% C02, 100 ⁇ l of ly ⁇ sis ⁇ olution (33% (v/v) N,N-dimetylformamide) , 20% (p/v) sodium dodecylsulfate, in water, brought to pH 4.7 with glacial acetic acid) were added to each well. The solu ⁇ tions were mixed in the wells with a multi-channel pi- pette and incubated for 24 h at 37 ⁇ C. The absorbance of each well was then read by a multi-channel microplate reader at 570 and 650 nm (reference).
  • MTT thiazolyl blue solution
  • the cytotoxic activity was calculated by interpola ⁇ tion of the ab ⁇ orbances on a calibration curve obtained with non-biotinylated TNF.
  • TTNNFF AA 00 ((nnoonn bbiioottiinnyyll.. )) -- 1.0 x 10 8 bio-TNF B 1/66 6.8 5 x 10 7 bio-TNF C 1/66 7.8 2.5 x 10 7 bio-TNF D 1/66 8.8 3.1 x 10 7 bio-TNF E 1/138 8.8 3.9 x 10 6 bbiioo--TTNNFF FF 11//227755 88..88 3.0 x 10 5 bio-TNF G 1/550 8.8 1.0 x 10 5
  • the experiment is aimed at demonstrating that the constitution of artificial receptors on tumoral cells through the biotinylated antibodies and neutravidin pre- targeting system remarkably increases the total amount of bio-TNF which can bind to the cells compared to the maximum amount which can bind to natural receptors. Moreover, this experiment is aimed at evaluating the association and dissociation times of bio-TNF with natural and artificial receptor ⁇ (neutravidin) from cells pre-treated with antibodies and neutravidin.
  • the cells were washed two times by adding 200 ⁇ l/well of PBS/FCS 2% and spinning for 2 min at 1300 rp .
  • the cells were resuspended by vortexing and mixed with 50 ⁇ l/well of 2% PBS/FCS and with 1 ⁇ l of 2.5 mg/ml neutravidin in PBS/FCS 2% (neutravidin's final concentration 50 mg/ml). After 10 min incubation on ice, cells were washed two times again with 2% PBS/FCS, as above.
  • 100,000 cells in 50 ⁇ l 2% PBS/FCS were seeded in 8 wells of a round bottomed plate, mixed with 1 ⁇ l of bio- 19E12 mAb, 0.5 mg/ml in 2% PBS/FCS (antibody's final concentration 10 mg/ml), and incubated for 10 min on ice.
  • Cells were washed two times by adding 200 ⁇ l/well of 2% PBS/FCS and centrifuged for 2 min at 1300 rpm. Cells were resuspended by vortexing and mixed with 50 ⁇ l/well of 2% PBS/FCS and with 1 ⁇ l neutravidin 2.5 mg/ml in 2% PBS/FCS (final neutravidin concentration 50 ⁇ g/ml). After 10 min incubation on ice, cells were washed two times again with 2% PBS/FCS, as above.
  • the 8 samples were washed with 200 ⁇ l of 2% PBS/FCS by centrifugation (twice). Cells were resuspended in 50 ⁇ l of RPMI, 5% FCS, 2 M glutam ine, 100 IU/ml penicillin, 100 ⁇ g/ml streptomycin, 250 ng/ml amphotericin B, and at different moments, fixed with 0.25% paraformaldehyde for 1 h at 4"C.
  • the neutravidin pre-targeting on the cells provokes an at least 10-20 times higher increase in the bio-TNF binding to the cells, compared to the binding obtainable with the sole natural receptors (determined without neutravidin or using non-biotinylated TNF). The best increase was observed with bio-TNF cod.#B (biotinylated at pH 6.8) (data not shown).
  • Example 1.5 Comparison of TNF and bio-TNF citotoxicitie ⁇ on tumoral cells pre-treated with biotinylated antibodies and neutravidin, in vitro r in the presence of actinorrtycin D
  • the example is aimed at demon ⁇ trating the ability of a biotinilated antibody/avidin system to deliver biotin-TNF on the cell surface in the bilogical active form and to increase the in vitro citotoxicity of the same, compared to that obtainable simply using the natural receptors.
  • the experiment was conducted by sequentially incubating and washing the cells with a) mAb bio-19E12, b) neutravidin, c) bio-TNF.
  • a) mAb bio-19E12 a) neutravidin
  • c) bio-TNF a) mAb bio-19E12
  • the cytotoxicity test was carried out in the presence of a transcription inhibitor (actinomycin D).
  • the suspension was incubated for 10 min on ice. Cells were washed two times by adding 200 ⁇ l/well of 2%
  • TNF and bio-TNF are weakly cytotoxic for RMA cells in the absence of neutravidin
  • actinomycin D both TNF and bio-TNF have shown no cytotoxic activity at all (data not ⁇ hown).
  • Example 1.6 Comparison of the in vivo tumorigenicity (mouse) of RMA Thy 1.1 cl2 cells pre-treated with biotinylated antibodies, neutravidin and with TNF or bio-TNF, in the absence of Actinomycin D
  • This experiment is aimed at demonstrating the reduced in vivo tumorigenicity of cells pre-treated with bio-TNF bound to the cellular surface through the antibody-biotin-neutravidin system (artificial receptor), compared to cells pre-treated with TNF or with bio-TNF exclusively bound to the natural receptors.
  • the adopted model is based on the subcutaneous administration of RMA Thy 1.1 Cl.2 cells pre-treated X, vitro. The experiment was carried out using 4 groups o. female C57 BL6 mice (5 mice for each group) and measuring the diameter of the tumoral mass at different days. Mice were treated with pre-treated cells as ⁇ hown in table 2.
  • TNF and bio-TNF used in this study are such as to determine partial cytotoxic effects only in the presence of actinomycin D, as demonstrated in the example 1.5 (fig. 2).
  • cells were treated in the total absence of actinomycin D, i.e. in conditions according to wich both TNF and bio-TNF are not cytotoxic.
  • Cells were washed two times by adding 200 ⁇ l/well of 2% PBS/FCS and spinning 2 min at 1,300 rpm. Cells were resuspended by vortexing and mixed with 50 ⁇ l/well of 2% PBS/FCS and with 1 ⁇ l of neutravidin 0.5 mg/ml in 2% PBS/FCS. After 10 min incubation on ice, cells were washed two times again with 2% PBS/FCS, as above. Then, 50 ⁇ l of 2% PBS/FCS, 1 ⁇ l of TNF or bio-TNF at a respective concentration of 50,000 and 10,000 U/ml, were added to each well, and incubated for 15 min on ice.
  • 5 3 3 5 10 mean 3.6 5 7.5 10.3 1231
  • Example 2 This example shows an application of the invention based on the system:
  • Pathological target A: B: C-cytokine release-inducer where:
  • C-cytokine release-inducer biotin-lipopolysaccharide conjugate (LPS) and where
  • (-) represents a covalent bond
  • Biotinamidocaproylhydrazide Sigma B-3770 Tris base: BDH cod. 10235
  • Solutions - "Stop solution” 0.1 M Tris-HCl pH 7.5 (in water)
  • OPD tablet 5 mg: Sigma P 6912.
  • H 2 S0 4 BDH 10276-5G H 2 0 2 : Carlo Erba A902011404.
  • PBS 0.15 M NaCl, 0.05 M Na-phosphate pH 7.3.
  • OPD 2 tablets in 15 ml distilled water and 20 ml
  • the plate was washed three time ⁇ with PBS. 100 ⁇ l ⁇ treptavidin-HRP 1:2000 in 0.5% PBS/BSA / 0.05% Tween were added to each well. After 1 h incubation at 37*C, the plate was wa ⁇ hed three times with 0.05% PES-Tween.
  • Biotin-LPS ( ⁇ g/ml) Optical density (492 nm)
  • This experiment is aimed at demonstrating the reduced in vivo tumorigenicity of cell ⁇ pre-treated with bio LPS bound to the cellular surface through the antibody-biotin-neutravidin system (artificial recep- tor), compared to cells pre-treated with LPS.
  • the employed model is based on the s.c. administration of RMA Thy 1.1 Cl.2 cells pre-treated n vitro.
  • the experiment wa ⁇ carried out using 3 groups of
  • mice C57 BL6 female mice (5 mice each) and measuring the diameter of the tumoral mass at different days. Mice were treated with pre-treated cell ⁇ as indicated in table 4.
  • mice C1.2 cells injected into mice.
  • TNF Characterization at the molecular and cellular and in vivo levels. FEBS Lett. 285, 199- 212.
  • Necrosi ⁇ Factor The Molecule ⁇ and their emerging roles in medicine, ed. B. Beutler Raven Pre ⁇ , Ltd, New York, pp 283-406.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une nouvelle méthode d'utilisation thérapeutique des cytokines et de nouveaux produits pour la mise en oeuvre de cette méthode. La méthode est basée sur l'administration séquentielle d'un composant A (par exemple un antibiotique biotinylé) capable d'amener, vers une cible particulière atteinte d'une pathologie, un second composant B (par exemple de l'avidine), suivie par celle d'un composant capable de se lier au composant B comme par exemple la biotine (composant C), conjugué avec les cytokines. Le procédé permet d'augmenter la concentration locale en cytokines modifiées (cytokines C) par l'interaction avec le récepteur 'artificiel' B et de provoquer une réponse biologique locale assurée par les récepteurs 'naturels'.
EP97903285A 1996-02-27 1997-02-14 Cytokines modifiees pour usage therapeutique Withdrawn EP0885015A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT96MI000358A IT1282692B1 (it) 1996-02-27 1996-02-27 Citochine modificate per l'uso in terapia
ITMI960358 1996-02-27
PCT/EP1997/000704 WO1997031655A2 (fr) 1996-02-27 1997-02-14 Cytokines modifiees pour usage therapeutique

Publications (1)

Publication Number Publication Date
EP0885015A2 true EP0885015A2 (fr) 1998-12-23

Family

ID=11373397

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97903285A Withdrawn EP0885015A2 (fr) 1996-02-27 1997-02-14 Cytokines modifiees pour usage therapeutique

Country Status (6)

Country Link
EP (1) EP0885015A2 (fr)
JP (1) JP2000506835A (fr)
AU (1) AU1769497A (fr)
CA (1) CA2247308A1 (fr)
IT (1) IT1282692B1 (fr)
WO (1) WO1997031655A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012554A1 (fr) * 1998-08-28 2000-03-09 Commissariat A L'energie Atomique Procede de synthese d'une chimiokine marquee, chimiokine marquee et trousse d'analyse
FR2783528A1 (fr) * 1998-08-28 2000-03-24 Commissariat Energie Atomique Procede de synthese d'une chimiokine marquee, chimiokine marquee et trousse d'analyse
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
EP2244738B1 (fr) * 2008-01-25 2020-03-04 Gavish-Galilee Bio Applications Ltd Ciblage d'un site tumoral pour susciter la réponse immune innée
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
KR20160138177A (ko) 2014-03-21 2016-12-02 애브비 인코포레이티드 항-ｅｇｆｒ 항체 및 항체 약물 접합체
CA3027045A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-b7-h3 et conjugues anticorps-medicaments
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
CA3027103A1 (fr) 2016-06-08 2017-12-14 Abbvie Inc. Anticorps anti-b7-h3 et conjugues anticorps-medicaments
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
US11932694B2 (en) 2017-04-19 2024-03-19 Bluefin Biomedicine, Inc. Anti-VTCN1 antibodies and antibody drug conjugates
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578287A (en) * 1992-06-09 1996-11-26 Neorx Corporation Three-step pretargeting methods using improved biotin-active agent
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
EP0733066B1 (fr) * 1993-12-07 2003-11-19 NeoRx Corporation Procedes et composes de preciblage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9731655A2 *

Also Published As

Publication number Publication date
WO1997031655A3 (fr) 1997-11-13
ITMI960358A0 (fr) 1996-02-27
ITMI960358A1 (it) 1997-08-27
WO1997031655A2 (fr) 1997-09-04
IT1282692B1 (it) 1998-03-31
JP2000506835A (ja) 2000-06-06
CA2247308A1 (fr) 1997-09-04
AU1769497A (en) 1997-09-16

Similar Documents

Publication Publication Date Title
Curnis et al. NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors
Shibata et al. Functionalization of tumor necrosis factor-α using phage display technique and PEGylation improves its antitumor therapeutic window
US20050265965A1 (en) Modified cytokines for use in cancer therapy
EP0885015A2 (fr) Cytokines modifiees pour usage therapeutique
JP2002504811A (ja) 胃腸管（ｇｉｔ）輸送受容体に結合するランダムペプチド、及び関連した方法
JPH10502334A (ja) 受容体調節剤およびこれに関連した方法
Kang et al. Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin
Schechter et al. Polymers in drug delivery: immunotargeting of carrier-supported cis-platinum complexes
EP1562620B1 (fr) Cytokines modifiees a utiliser dans la therapie contre le cancer
JP2003513985A (ja) 天然に存在しないエナンチオマー（Ｌ−ビオチン）を結合する抗体および該抗体のターゲッティング薬剤（ａｇｅｎｔ）としての使用
Svensson et al. Synthesis and Characterization of Monoclonal Antibody-. beta.-Lactamase Conjugates
US20030157056A1 (en) Modified cytokines for use in cancer therapy
WO1999065529A1 (fr) Complexes de cobalamine et d'acide nucleique et leur utilisation en therapie genique
CN115590965B (zh) 用于治疗和/或预防hiv相关疾病的aptc偶联物及其应用
CN109152845A (zh) 含有在环内包含至少两个(-ch2-ch2-o-)单元的接头的缀合物和缀合试剂
Factor Tumor Cell Targeting with Antibody-Avidin Complexes and

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980916

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB IE IT LI NL SE

17Q First examination report despatched

Effective date: 20010330

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 47/48 A, 7A 61P 35/00 B, 7A 61P 31/00 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021217